

# Claudia Balducci

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4249131/claudia-balducci-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62  
papers

2,929  
citations

32  
h-index

53  
g-index

66  
ext. papers

3,399  
ext. citations

6.4  
avg, IF

5.17  
L-index

#	Paper	IF	Citations
62	TLR4 in Neurodegenerative Diseases: Alzheimer's and Parkinson's Diseases. <i>Agents and Actions Supplements</i> , <b>2021</b> , 105-118	0.2	
61	Accelerating Alzheimer's disease drug discovery and development: what's the way forward?. <i>Expert Opinion on Drug Discovery</i> , <b>2021</b> , 16, 727-735	6.2	4
60	Intranasal delivery of mesenchymal stem cell secretome repairs the brain of Alzheimer's mice. <i>Cell Death and Differentiation</i> , <b>2021</b> , 28, 203-218	12.7	20
59	Inflammation and Parkinson's disease pathogenesis: Mechanisms and therapeutic insight. <i>Progress in Molecular Biology and Translational Science</i> , <b>2021</b> , 177, 175-202	4	6
58	Sleep inhibition induced by amyloid- $\beta$ oligomers is mediated by the cellular prion protein. <i>Journal of Sleep Research</i> , <b>2021</b> , 30, e13187	5.8	1
57	A critical appraisal of tau-targeting therapies for primary and secondary tauopathies. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	3
56	Deletion of calcineurin from astrocytes reproduces proteome signature of Alzheimer's disease and epilepsy and predisposes to seizures. <i>Cell Calcium</i> , <b>2021</b> , 100, 102480	4	2
55	Flavonoid-Derived Human Phenyl- $\beta$ -Valerolactone Metabolites Selectively Detoxify Amyloid- $\beta$ Oligomers and Prevent Memory Impairment in a Mouse Model of Alzheimer's Disease. <i>Molecular Nutrition and Food Research</i> , <b>2020</b> , 64, e1900890	5.9	16
54	Neuroprotective Effects of Doxycycline in the R6/2 Mouse Model of Huntington's Disease. <i>Molecular Neurobiology</i> , <b>2020</b> , 57, 1889-1903	6.2	20
53	Assessment of plaque morphology in Alzheimer's mouse cerebellum using three-dimensional X-ray phase-based virtual histology. <i>Scientific Reports</i> , <b>2020</b> , 10, 11233	4.9	8
52	X-ray Phase Contrast Tomography Serves Preclinical Investigation of Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , <b>2020</b> , 14, 584161	5.1	3
51	Doxycycline for Alzheimer's Disease: Fighting $\beta$ Amyloid Oligomers and Neuroinflammation. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 738	5.6	32
50	Biophysical and in Vivo Studies Identify a New Natural-Based Polyphenol, Counteracting A $\beta$ Oligomerization in Vitro and A $\beta$ Oligomer-Mediated Memory Impairment and Neuroinflammation in an Acute Mouse Model of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 4462-4475	5.7	14
49	Neuroinflammation and the Gut Microbiota: Possible Alternative Therapeutic Targets to Counteract Alzheimer's Disease?. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 284	5.3	56
48	Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects. <i>Brain</i> , <b>2019</b> , 142, 249-254	11.2	27
47	Plasma and Brain Concentrations of Doxycycline after Single and Repeated Doses in Wild-Type and APP23 Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 368, 32-40	4.7	28
46	Exploring Alzheimer's disease mouse brain through X-ray phase contrast tomography: From the cell to the organ. <i>NeuroImage</i> , <b>2019</b> , 184, 490-495	7.9	33

45	Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. <i>Brain, Behavior, and Immunity</i> , <b>2018</b> , 69, 591-602	16.6	40
44	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. <i>ACS Chemical Neuroscience</i> , <b>2018</b> , 9, 1591-1606	5.7	13
43	Novel targets in Alzheimer's disease: A special focus on microglia. <i>Pharmacological Research</i> , <b>2018</b> , 130, 402-413	10.2	31
42	Alzheimer's Disease, Oligomers, and Inflammation. <i>Journal of Alzheimers Disease</i> , <b>2018</b> , 62, 1261-1276	4.3	89
41	Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. <i>Neurobiology of Aging</i> , <b>2018</b> , 70, 128-139	5.6	31
40	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2018</b> , 14, 609-618	6	67
39	Toll-like receptor 4-dependent glial cell activation mediates the impairment in memory establishment induced by Amyloid oligomers in an acute mouse model of Alzheimer's disease. <i>Brain, Behavior, and Immunity</i> , <b>2017</b> , 60, 188-197	16.6	87
38	Multifunctional liposomes delay phenotype progression and prevent memory impairment in a presymptomatic stage mouse model of Alzheimer disease. <i>Journal of Controlled Release</i> , <b>2017</b> , 258, 121-127	11.7	26
37	Retro-inverso peptide inhibitor nanoparticles as potent inhibitors of aggregation of the Alzheimer's Aβ peptide. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , <b>2017</b> , 13, 723-732	6	39
36	Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model. <i>Nano Research</i> , <b>2016</b> , 9, 2190-2201	10	13
35	Internalization of nanopolymeric tracers does not alter characteristics of placental cells. <i>Journal of Cellular and Molecular Medicine</i> , <b>2016</b> , 20, 1036-48	5.6	4
34	The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers. <i>Journal of Alzheimers Disease</i> , <b>2016</b> , 53, 1485-97	4.3	8
33	Oligomeropathies and pathogenesis of Alzheimer and Parkinson's diseases. <i>Movement Disorders</i> , <b>2016</b> , 31, 771-81	7	66
32	Transgenic fatal familial insomnia mice indicate prion infectivity-independent mechanisms of pathogenesis and phenotypic expression of disease. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1004796	7.6	45
31	The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. <i>Journal of Alzheimers Disease</i> , <b>2015</b> , 46, 471-82	4.3	20
30	Striatum and entorhinal cortex atrophy in AD mouse models: MRI comprehensive analysis. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 776-88	5.6	23
29	Multifunctional liposomes reduce brain Amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models. <i>Journal of Neuroscience</i> , <b>2014</b> , 34, 14022-31	6.6	112
28	In vivo application of beta amyloid oligomers: a simple tool to evaluate mechanisms of action and new therapeutic approaches. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 2491-505	3.3	47

27	The neurodegeneration in Alzheimer disease and the prion protein. <i>Prion</i> , <b>2013</b> , 7, 60-5	2.3	12
26	An N-terminal fragment of the prion protein binds to amyloid- $\beta$ oligomers and inhibits their neurotoxicity in vivo. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 7857-7866	5.4	142
25	The $\beta$ -secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. <i>Journal of Alzheimers Disease</i> , <b>2011</b> , 24, 799-816	4.3	44
24	APP transgenic mice: their use and limitations. <i>NeuroMolecular Medicine</i> , <b>2011</b> , 13, 117-37	4.6	54
23	c-Jun N-terminal kinase regulates soluble A $\beta$ oligomers and cognitive impairment in AD mouse model. <i>Journal of Biological Chemistry</i> , <b>2011</b> , 286, 43871-43880	5.4	65
22	$\beta$ Amyloid oligomers and prion protein: Fatal attraction?. <i>Prion</i> , <b>2011</b> , 5, 10-5	2.3	20
21	Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. <i>Gene Therapy</i> , <b>2010</b> , 17, 643-52	4	56
20	Cognitive deficits associated with alteration of synaptic metaplasticity precede plaque deposition in ABP23 transgenic mice. <i>Journal of Alzheimers Disease</i> , <b>2010</b> , 21, 1367-81	4.3	34
19	Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 2295-300	11.5	371
18	Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease. <i>Brain</i> , <b>2010</b> , 133, 3323-35	11.2	57
17	Neuropeptide Y overexpression using recombinant adeno-associated viral vectors. <i>Neurotherapeutics</i> , <b>2009</b> , 6, 300-6	6.4	31
16	Mutant prion protein expression causes motor and memory deficits and abnormal sleep patterns in a transgenic mouse model. <i>Neuron</i> , <b>2008</b> , 60, 598-609	13.9	80
15	Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. <i>Brain</i> , <b>2008</b> , 131, 1506-15	11.2	134
14	NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. <i>Hippocampus</i> , <b>2008</b> , 18, 564-74	3.5	47
13	Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. <i>Neuropsychopharmacology</i> , <b>2006</b> , 31, 757-67	8.7	150
12	The serotonin 5-HT2A receptors antagonist M100907 prevents impairment in attentional performance by NMDA receptor blockade in the rat prefrontal cortex. <i>Neuropsychopharmacology</i> , <b>2004</b> , 29, 1637-47	8.7	86
11	Reversal of visual attention dysfunction after AMPA lesions of the nucleus basalis magnocellularis (NBM) by the cholinesterase inhibitor donepezil and by a 5-HT1A receptor antagonist WAY 100635. <i>Psychopharmacology</i> , <b>2003</b> , 167, 28-36	4.7	32
10	Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. <i>European Journal of Neuroscience</i> , <b>2003</b> , 18, 143-8	3.5	158

9	Time-dependent induction of angiogenic-like effects after central infusion of urocortin or corticotropin-releasing factor in the rat. <i>Psychopharmacology</i> , <b>2002</b> , 160, 113-21	4.7	69
8	Stimulation of 5-HT(1A) receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. <i>Psychopharmacology</i> , <b>2001</b> , 158, 39-47	4.7	23
7	Low doses of 8-OH-DPAT prevent the impairment of spatial learning caused by intrahippocampal scopolamine through 5-HT(1A) receptors in the dorsal raphe. <i>British Journal of Pharmacology</i> , <b>2000</b> , 131, 375-81	8.6	33
6	S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. <i>British Journal of Pharmacology</i> , <b>1999</b> , 128, 1207-14	8.6	33
5	WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by blockade of hippocampal NMDA receptors. <i>Neuropharmacology</i> , <b>1999</b> , 38, 1165-73	5.5	41
4	Gamma-hydroxybutyric acid decreases intravenous cocaine self-administration in rats. <i>Pharmacology Biochemistry and Behavior</i> , <b>1998</b> , 59, 697-702	3.9	12
3	Dextromethorphan reduces intravenous cocaine self-administration in the rat. <i>European Journal of Pharmacology</i> , <b>1997</b> , 321, 279-83	5.3	44
2	Dopamine partial receptor agonists reduce ethanol intake in the rat. <i>European Journal of Pharmacology</i> , <b>1996</b> , 296, 233-8	5.3	18
1	Inhibition of nitric oxide synthesis reduces intravenous cocaine self-administration in the rat. <i>Neuropharmacology</i> , <b>1996</b> , 35, 1811-4	5.5	28